Senyint AI Completes Series B+ Financing and Onboards Top-Tier Industry Experts

VCBeat (WeChat ID: vcbeat) has learned that SYNYI·AI announced the completion of its Series B+ financing round, led by Xianghe Capital. Following this round, SYNYI·AI’s cumulative fundraising has exceeded RMB 300 million.

Xianghe Capital is a venture capital fund co-founded by Tang Hesong, former Vice President of Strategic Investment and M&A at Baidu, and Executive Director Yang Liu (Maggie), focusing on early-stage and growth-stage opportunities in the TMT (Technology, Media, and Telecommunications) sectors. Mr. Tang previously led and oversaw Baidu’s strategic investment and M&A activities, orchestrating a series of high-impact deals in China’s internet industry, including investments in iQIYI, Qunar, PPS, and 91 Wireless. Maggie assisted Mr. Tang in completing these major investment and M&A transactions and independently led investments in companies such as Kuaishou, Uxin, and Lianjia.

The Xianghe team possesses strong strategic analysis capabilities and extensive investment experience. In the mere two years since its establishment, Xianghe Capital has invested in a portfolio of outstanding star projects, including iQIYI, VIPKID, Zuoyebang, Yunmanman, Huolala, Kuaikan Manhua, Sensors Data, and Infervision.

Regarding the rationale behind investing in SYNYI·AI, Tang Hesong, Co-Founding Partner of Xianghe Capital, stated: “We are highly optimistic about SYNYI·AI’s growth prospects. Healthcare represents a trillion-yuan market in China. By leveraging AI technologies such as natural language processing for data analysis and processing, SYNYI·AI creates value both by reducing labor costs and by assisting in the enhancement of diagnostic and treatment standards. The company’s ultimate goal is to improve healthcare quality and efficiency, which holds significant importance and potential. Furthermore, SYNYI·AI helps doctors and hospitals enhance efficiency in scientific research and management, effectively addressing critical pain points within the industry. Meanwhile, the accumulation and refinement of data and models will establish barriers to entry for its business model. Additionally, from an application perspective, medical AI in China is still in a relatively early stage, offering substantial opportunities and potential. As a leader in this sector, SYNYI·AI possesses competitive advantages in business insights, data accumulation, and product refinement. Moreover, with extensive data accumulation, continuous product iteration, and sustained brand strengthening, SYNYI·AI will maintain a sustainable competitive advantage.”

Beyond SYNYI·AI’s business model and the immense market potential of medical AI, Tang Hesong stated: “The team is the core factor in our investment decision. SYNYI·AI boasts an exceptional team, with a leadership tier that has clear strategic objectives and strong overall technical capabilities. In this vast market, they are engaged in value-creating work, and their commercial practices are at the forefront of the industry. CEO Zhang Shaodian is undoubtedly among the most outstanding entrepreneurs I have ever encountered. As an expert in medical informatics, he possesses deep technical expertise, robust research capabilities, and clear strategic thinking. He is thoughtful, a quick learner, decisive in making decisions, and resolute in execution—precisely the type of entrepreneur that Xianghe Capital favors.”

Zhang Shaodian, Founder and CEO of SYNYI·AI

It is reported that Zhang Shaodian, founder and CEO of SYNYI·AI, was born in 1988. He holds a Ph.D. in Medical Informatics from Columbia University in the United States, serves as a specially appointed researcher at the APEX Data and Knowledge Management Laboratory of the Department of Computer Science at Shanghai Jiao Tong University, and was recruited under the Pujiang Talent Plan. In 2017, he was named to the Forbes Asia 30 Under 30 list in the healthcare technology sector. His academic journey is exemplary: in September 2007, he was admitted to the ACM Pilot Class in Computer Science at Shanghai Jiao Tong University, widely regarded as the “Whampoa Military Academy” of computer science education in China. He began participating in scientific research projects during his junior year and was admitted to the Department of Medical Informatics at Columbia University after publishing papers on natural language processing during his internship at Microsoft Research Asia. During his doctoral studies, he achieved fruitful academic results, publishing more than ten papers in top international journals and conferences in medical informatics, including JAMIA, JBI, and AMIA. As of October 2018, his publications had been cited more than 600 times.

As a leading medical AI company in the industry, SYNYI·AI has not only made rapid progress in capital and business operations but has also recently attracted numerous top-tier talents from specialized fields, including Ms. Lü Jing, Vice President of Government and Corporate Affairs; Dr. Wang Fei, Chief Scientist; Mr. Xue Yanbo, Vice President of Product; and Mr. Fei Teng, Director of Corporate Development.

Lu Jing, Vice President of SYNYI·AI

In July this year, Ms. Lü Jing joined SYNYI·AI as Vice President of Government and Corporate Affairs and concurrently serves as Chief Spokesperson. She is responsible for managing strategic relationships and fostering collaborations with government bodies, media outlets, industry organizations, and other stakeholders. Reportedly, Ms. Lü previously served at Johnson & Johnson for over 19 years, holding positions such as Director of Government Affairs and Communications and Corporate Spokesperson at Shanghai Johnson & Johnson Pharmaceuticals Ltd. She has been honored with titles including “2014 China Communication Person of the Year,” “2014 Influential Brand Leader in China,” and “Top Ten Corporate Spokespersons in China” (an award she received again in 2010). She also holds an EMBA degree from HEC Paris. With extensive experience and a broad network accumulated through years of work in government affairs, public relations, and communications, Ms. Lü possesses unique and profound insights into government liaison and media engagement. Her appointment is expected to provide strong support and safeguard the development of SYNYI·AI’s various business initiatives.

Fei Teng, Director of the Corporate Development Department

This October, Mr. Fei Teng, formerly the youngest Project Director at China Renaissance, joined SYNYI·AI as Director of Corporate Development, taking full responsibility for the company’s strategy, capital markets, investor relations, and business partnerships. Mr. Fei boasts an outstanding track record in private equity financing, having led 29 private equity financing deals throughout his career with an industry-leading success rate. Previously, he served as a consultant at Accenture, providing strategic and management consulting services to Fortune 500 clients in the energy and healthcare sectors. Mr. Fei will play a pivotal role in building and advancing SYNYI·AI’s strategies in intelligence, investment and financing, and business development, further strengthening the company’s influence in the capital markets.

Dr. Fei Wang

This October, Dr. Wang Fei, a world-renowned scientist in medical artificial intelligence, has been appointed as Chief Scientist at SYNYI·AI. In this role, he will primarily lead efforts to overcome key technical challenges in AI and explore emerging trends in the field. Dr. Wang is a distinguished scholar in medical AI, with outstanding research achievements in electronic health record data, medical imaging, medical text analysis, and genomic data analysis, earning him an excellent reputation within the industry. He has served as Conference Chair or Program Committee Chair for several major international conferences in the field, and as an editorial board member for numerous leading industry journals. Dr. Wang has published over 200 papers in top-tier conferences and journals related to AI and medical informatics, which have been cited more than 7,000 times.

Xue Yanbo, Vice President of Products at SYNYI·AI

Prior to their arrival, Mr. Xue Yanbo joined the company as Vice President of Products, bringing with him over a decade of experience in R&D and product management within the Health Information Technology (HIT) sector. Previously, he served as a senior R&D executive at Winning Health, a publicly listed HIT company in China, and as Deputy General Manager of the Hospital Business Unit at Wonders Information. It is reported that Mr. Xue has participated in numerous international exchanges and collaborations, maintaining a keen understanding of global HIT development trends. He has overseen the construction of information platforms and standardized application projects for dozens of large hospitals in China, assisting clients in achieving Level 4 Grade A (the highest level at the time) in the National Interconnectivity Maturity Assessment and HIMSS Stage 6 certification. An expert certified in international HL7 V2.7, V3 RIM, and V3 CDA standards, Mr. Xue serves as an HL7 China trainer for HL7 V2.7 and CDA and co-chairs the FHIR Working Group.

Zhang Shaodian stated, “In addition to these seasoned senior executives, we have also attracted R&D, solutions, and engineering leaders from top-tier technology companies to join us. They will be responsible for technological research and development, working closely with our product and AI teams to create deeply implemented artificial intelligence solutions. The core competitiveness of SYNYI·AI lies in its ability to integrate healthcare and AI. The recent arrival of top talent with backgrounds in both healthcare and AI will enable them to make outstanding contributions to SYNYI’s development through their highly valuable academic achievements and profound industry experience. Following the completion of this financing round, SYNYI will continue to invest in R&D, expand and enhance its product portfolio, and provide truly valuable solutions and professional services to the industry and clients, thereby maintaining its technological leadership. The SYNYI team shares a unified goal: to leverage AI capabilities to optimize every medical decision and improve the quality and efficiency of healthcare services. In the future, we will continue to collaborate with government bodies, industry organizations, and medical institutions to better meet the growing healthcare needs of the public, providing advanced and robust technological support for the vigorous development of smart healthcare in the new era and the advancement of the Healthy China strategy.”